Table 4.
MRSA Clone | n | % | spa type/CC | SCCmec | Virulence factors | *% Antibiotic resistance | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PVL | TSST-1 | arcA | E | C | CN | CIP | SXT | |||||
t386-IV | 14 | 12.5 | t386/CC1 | IV | neg | neg | neg | 100 | 57.1 | 21.4 | 21.4 | 0 |
The European clone | 11 | 9.8 | t044/CC80 | IV | pos | neg | neg | 50 | 33.3 | 16.7 | 41.7 | 16.7 |
The Gaza clone | 10 | 8.9 | t223/CC1 | IV | neg | pos | neg | 45.5 | 18.2 | 18.2 | 9.1 | 27.3 |
t037-IV | 10 | 8.9 | t037/ CC8/239 | IV | neg | neg | neg | 40 | 20 | 80 | 80 | 10 |
USA-300 clone | 9 | 8 | t008/CC8 | IV | pos | neg | pos | 83.3 | 41.7 | 0 | 75 | 8 |
:E, Erythromycin; C, Clindamycin; CN, Gentamicin; CIP, Ciprofloxacin; SXT, Trimethoprim sulfamethoxazole.